Is self-reported adherence associated with clinical outcomes in women treated with anticholinergic medication for overactive bladder?

AimTo determine the association between self-reported adherence to anticholinergic medication and clinical outcomes in women with overactive bladder (OAB). MethodsA prospective study of women with OAB treated with fesoterodine for 8 weeks. Adherence to medication was measured using the Medication Adherence Self-report Inventory (MASRI). A self reported adherence rate of 80% was considered adherent. The association between self-reported adherence and clinical outcomes (Global Index of Improvement, Global impression of Severity, urinary symptom and quality of life scores) was examined. We hypothesized that adherent women would have greater improvement in urinary symptoms and quality of life than non-adherent women. ResultsBased on the MASRI, 115 (62.5%) women were adherent and 69 (37.5%) were non-adherent to anticholinergic medication at 8weeks. Adherent women were more likely to report overall improvement in their symptoms compared to non-adherent women (84% vs. 24%, P<0.001). Significantly more non-adherent women described their bladder symptoms as moderate or severe at 8 weeks compared to adherent women (74% vs. 44%, P=0.03). At 8 weeks, adherent women reported significantly greater improvement (change) in urinary symptoms from baseline to 8 weeks than non-adherent women (-13.325.8 vs. 2.5 +/- 14.4, P=0.04). Similarly, adherent women reported greater improvement in quality of life scores than non-adherent women (- 7.9 +/- 24.0 vs. -1.8 +/- 11.9, P=0.003). ConclusionSelf-reported non-adherence, as measured by the MASRI, is associated with clinically meaningful outcomes in women with OAB. This further validates the MASRI as a clinically useful tool for measuring adherence to anticholinergic medications in women with OAB. Neurourol. Urodynam. 35:738-742, 2016. (c) 2015 Wiley Periodicals, Inc.